Aditxt, Inc. reported a net loss of $42.8 million for the fiscal year ending December 31, 2025, compared to a loss of $35 million in the previous year. The company's revenue for 2025 was $3,195, a significant decrease from $133,985 in 2024, primarily attributed to a decline in orders for its AditxtScore™ product due to reduced COVID-19 testing. The cost of goods sold also decreased to $2,927 from $627,474, reflecting the same trend. The company's accumulated deficit now stands at $209.8 million, raising concerns about its ability to continue as a going concern without additional capital.
In terms of strategic developments, Aditxt formed two new subsidiaries in 2023: Adimune, Inc. and Adivir, Inc. Adimune focuses on immune modulation therapies, particularly its ADI-100 product candidate, which is designed to treat autoimmune diseases and improve organ transplant outcomes. The company has completed preclinical studies for ADI-100 and is preparing for clinical trials in Germany, with plans to collaborate with the Mayo Clinic for FDA submissions. Adivir aims to develop antiviral solutions for infectious diseases, emphasizing the need for improved treatment options in this area.
Operationally, Aditxt has made significant strides in its product development pipeline. The company has engaged a Contract Research Organization (CRO) to manage clinical trials for ADI-100 and has established a state-of-the-art laboratory in Richmond, Virginia, for its Pearsanta subsidiary, which focuses on early cancer detection through mitochondrial DNA analysis. As of December 31, 2025, Aditxt employed 26 full-time staff, reflecting its commitment to building a skilled workforce to support its innovative projects.
Despite these advancements, Aditxt faces challenges, including the need for substantial additional capital to fund ongoing operations and clinical trials. The company has indicated that its current cash reserves may not be sufficient to sustain operations for the next 12 months, creating uncertainty about its future. Aditxt's management is exploring various funding options, including equity and debt financing, to address its financial needs and continue its product development efforts.
Looking ahead, Aditxt's management remains optimistic about the potential of its product candidates and the strategic direction of the company. However, the success of its initiatives will depend on securing necessary funding, navigating regulatory approvals, and achieving market acceptance for its innovative therapies. The company is actively working to address its financial challenges while advancing its research and development efforts in the healthcare sector.
About Aditxt, Inc.
Aditxt, Inc. develops and commercializes innovative health technologies through a collaborative ecosystem that integrates licensing, development, and commercialization. Its portfolio includes immune modulation therapies, precision health diagnostics, and mitochondrial DNA-based biomarker platforms targeting autoimmune diseases, cancer, and infectious diseases. The company partners with research institutions and healthcare providers to advance personalized and population health solutions, leveraging proprietary technologies and a systemized approach to transform promising innovations into scalable, market-ready products.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov